AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca core SG&A expense ($M) ($M)
Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation
Latest, FY2025
-15,534
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
-15,028 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core SG&A expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -15,534 | +3.4% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -15,028 | +9.4% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | -13,739 | +7.1% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -12,826 | +15.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | -11,104 | +18.6% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | -9,362 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up core sg&a expense ($m)
- Core SG&A expense (% of total revenue)26.0% · FY2025
- Core SG&A expense YoY actual (%)3.0% · FY2025
- Core SG&A expense YoY CER (%)3.0% · FY2025
- Reported (IFRS) SG&A expense ($M)-19,933 · FY2025
- Reported (IFRS) SG&A expense (% of total revenue)34.0% · FY2025
- Core distribution expense ($M)-579 · FY2025
- Core other operating income & expense ($M)383 · FY2025
Cite this data
StockData. (2026). AstraZeneca Core SG&A expense ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core_sga
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.